Monday, June 7, 2004, including Plenary Sessions
OncoLink's ASCO Coverage made possible by an unrestricted Educational Grant from Bristol-Myers Squibb Oncology.
A historical perspective on the American Society of Clinical Oncology (ASCO) A multicenter phase III comparison of docetaxel + prednisone and mitoxantrone + prednisone in patients with hormone-refractory prostate cancer A multicenter, phase III randomized trial for stage IIIb/IV NSCLC of weekly paclitaxel and carboplatin vs. standard paclitaxel and carboplatin given every three weeks, followed by weekly paclitaxel A randomized comparison of single agent carboplatin with radiotherapy in the adjuvant treatment of stage I seminoma of the testis following orchiectomy: MRC TE19/EORTC 30982 Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a radomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. Eliminating the Suffering and Death from Cancer: A Cancer Center Director's Experience Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126 HMG CoA reductase inhibitors and the risk of colorectal cancer Long-term effects of conservation therapy for muscle invasive bladder carcinoma Preliminary evidence of relationship between genetic markers and oncology patient quality of life Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC) : ' Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) Risk-adapted management of stage I seminoma: the second Spanish Germ Cell Cancer Group (GG) study SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (P) in men with androgen-independent prostate cancer (AIPCA) What we learned on Monday June 7, 2004